Treating high-risk childhood leukemia in Korea
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment plan for children with very high-risk acute lymphoblastic leukemia. It aims to improve outcomes for patients whose leukemia has specific genetic markers or has not responded well to initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 19 years old when diagnosed with acute lymphoblastic leukemia.
- Your leukemia has one of these features: Philadelphia chromosome, failed to go into remission after first treatment, very low chromosome count, E2A-HLF gene change, or persistent leukemia after certain treatment phases.
- You cannot have any medical condition that would make the study drugs unsafe.
- If you are of childbearing age, you must use birth control and not be pregnant or breastfeeding.
- You are not taking part in any other interventional research study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This trial tests a new treatment approach for children and teens with high-risk acute lymphoblastic leukemia (ALL). It aims to improve outcomes for those with certain genetic changes or cancer that has spread.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
Hear when a new Acute Lymphoblastic Leukemia, Pediatric trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.